Henry Schein Announces $750 Million Share Repurchase Plan

Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care products and services to office-based dental and medical practitioners, announced today that its Board of Directors has authorized the repurchase of up to $750 million of shares of the Company’s common stock.

This program is in addition to the $500 million repurchase program announced in January 2025, which is anticipated to be fully executed by the end of the first quarter of 2026.

The Company had approximately 118.6 million shares outstanding as of September 8, 2025. This new authorization represents approximately 9.0 percent of shares outstanding at the current stock price. Purchases may be made from time to time in the open market, or through negotiated transactions.

“Henry Schein’s decision to repurchase shares reflects the confidence we have in our 2025–2027 BOLD+1 Strategic Plan and its potential to deliver sustainable growth and value,” said Ronald N. South, Senior Vice President and Chief Financial Officer. “With the support of a strong balance sheet, we are well positioned to serve our markets and further expand the depth and reach of our health care solutions.”

About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.